$ATEX

Ashe Gena L sold $1.4M of ATEX

Ashe Gena L (Chief Legal Officer & Corp Sec) sold 17,711 shares of Anterix Inc. (ATEX) at an average of $81.31 ($81.04–$82.14, $1.44M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · Ashe Gena L
Published Jun 17, 2026, 11:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest fact is the June 15 open-market sale by the Chief Legal Officer totaling ~$1.44M; no other company events (earnings, guidance, contracts, litigation) are included.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without additional catalysts.

03

What to watch

Insider sales can be driven by diversification, tax, or personal liquidity needs; the article provides no stated reason or broader insider-trading pattern.

Relevance 6/10Novelty 3/10Timing: Filed June 17; sale executed June 15.

Background

The article is an SEC Form 4 insider transaction disclosure for Anterix (ATEX).

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

Anterix (ATEX) insider Form 4 shows Chief Legal Officer Ashe Gena L sold 17,711 shares for about $1.44M at ~$81–$82.

Expected impact

Limited near-term impact; any effect is likely short-lived unless follow-on selling is disclosed.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific catalyst in the text.

Market effects

No sector-level read-through provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Because the insider sale is not explicitly tied to a pre-arranged 10b5-1 plan, some traders may view it as a stronger negative signal than typical routine sales.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider sale disclosure; ticker ATEX.

  • Ashe Gena L

    Chief Legal Officer & Corp Sec who sold 17,711 shares on June 15.

Related articles

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2